More Than You Think: The Hidden Burden of Severe Hypoglycemia in T1D-Scenario 3

Scenario 3 - Summary & Key Learning Points

Pdf Summary

The document summarizes ADA 2026 guidance on prescribing glucagon and improving emergency preparedness for severe hypoglycemia, emphasizing that glucagon access and caregiver training should be routine for anyone at risk.

<strong>Core ADA recommendation (6.16, Grade A):</strong> Glucagon should be prescribed to all people using insulin and to anyone at high risk for hypoglycemia. Support persons (family, caregivers, school staff) must know where it is stored and be trained to administer it. <strong>Ready-to-use products (no reconstitution) are preferred</strong> (Grade B).

<strong>Who should receive glucagon:</strong> all insulin users (any regimen) and high-risk groups including those with prior severe (Level 3) hypoglycemia, impaired awareness, sulfonylurea/meglitinide use, chronic kidney disease, adults ≥75 years, or cognitive impairment.

<strong>Prescribing gap:</strong> Real-world fill rates are very low (historically ~1.45% in type 1 diabetes; ~5% even after prior severe events; more recent short-acting insulin users ~8.3%). Key barriers include clinician inertia, perceived complexity of older reconstituted kits, cost misconceptions (ready-to-use can reduce overall system costs), and lack of training infrastructure. The proposed fix is <strong>systematic review of glucagon access at every visit</strong>.

<strong>Formulations compared:</strong> nasal glucagon powder, prefilled injectable devices, dasiglucagon (autoinjector/prefilled), and traditional reconstitution kits. Ready-to-use options generally have faster/easier administration and high success rates; traditional kits are least preferred due to reconstitution steps.

<strong>Patient-specific selection:</strong> nasal glucagon is favored for needle phobia, elderly/dexterity-limited helpers, people living alone, and when fastest/easiest use is critical. Injectable ready-to-use options may be preferred for weight-based pediatric dosing or formulary reasons. Reconstituted kits should be avoided except for rare insurance barriers.

<strong>Preparedness and training:</strong> People living alone need CGM sharing, nearby trained helpers, medical alert identification, multiple glucagon locations, an access plan, and tech backups. Caregiver training must include recognition, when/how to give glucagon with <strong>return demonstration</strong>, and post-use actions (positioning, calling 911, feeding after recovery), with documentation and annual refreshers.

<strong>Best practices/pitfalls:</strong> Always prescribe glucagon for insulin users, choose ready-to-use products, train multiple helpers (not just the patient), create a written emergency plan, and re-check supply/expiration and caregiver knowledge at every visit.

Keywords

ADA 2026 glucagon guidance

severe hypoglycemia emergency preparedness

glucagon prescribing for insulin users

caregiver training for glucagon administration

ready-to-use glucagon products

nasal glucagon powder

dasiglucagon autoinjector

hypoglycemia impaired awareness risk

glucagon access and refill rates gap

written hypoglycemia emergency action plan